New patient trials surrounding Retatrutide , specifically the 120mg formulation referred to as ZPHC, indicate a significant effect on physique decrease and associated metabolic conditions . Researchers believe that this dual compound, affecting both GLP-1 and GIP receptors , has the potential to represent a major improvement in the treatment of… Read More